United Therapeutics (UTHR) CFO sells 10,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share and acquired the related common shares.

On the same March 26, 2026, he sold a total of 10,000 common shares in multiple open‑market transactions at weighted average prices around $532–$540, pursuant to a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025. Following these transactions, he directly owned 18,876 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO AND TREASURER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/26/2026		M(1)		10,000	A	$135.42	28,876	D
Common Stock	03/26/2026		S(1)		991	D	$532.0242(2)	27,885	D
Common Stock	03/26/2026		S(1)		510	D	$532.9295(3)	27,375	D
Common Stock	03/26/2026		S(1)		609	D	$533.913(4)	26,766	D
Common Stock	03/26/2026		S(1)		1,847	D	$534.9763(5)	24,919	D
Common Stock	03/26/2026		S(1)		2,003	D	$535.9418(6)	22,916	D
Common Stock	03/26/2026		S(1)		1,577	D	$536.8985(7)	21,339	D
Common Stock	03/26/2026		S(1)		1,149	D	$537.8994(8)	20,190	D
Common Stock	03/26/2026		S(1)		994	D	$538.9134(9)	19,196	D
Common Stock	03/26/2026		S(1)		320	D	$540.0438(10)	18,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$135.42	03/26/2026		M(1)			10,000	03/15/2023	03/15/2027	Common Stock	10,000	$0.00	142,500	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $531.42 to $532.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $532.42 to $533.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $533.45 to $534.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $534.48 to $535.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $535.48 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $536.48 to $537.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $537.50 to $538.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $538.61 to $539.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $539.66 to $540.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did United Therapeutics (UTHR) CFO James Edgemond report in this Form 4?

CFO and Treasurer James Edgemond reported exercising stock options for 10,000 shares and selling 10,000 common shares of United Therapeutics in open‑market trades on March 26, 2026, under a pre‑arranged Rule 10b5‑1 trading plan.

How many United Therapeutics shares did the CFO sell and at what prices?

James Edgemond sold 10,000 common shares of United Therapeutics in multiple trades at weighted average prices ranging roughly from $531.42 to $540.36, according to footnote disclosures describing the execution ranges for each open‑market sale tranche.

What stock options did the United Therapeutics CFO exercise in this filing?

He exercised a stock option covering 10,000 shares of United Therapeutics common stock at an exercise price of $135.42 per share. The option had an original exercise date of March 15, 2023 and an expiration date of March 15, 2027.

Was the United Therapeutics CFO’s share sale part of a Rule 10b5-1 plan?

Yes. A footnote states the option exercise and subsequent share sales were made pursuant to a Rule 10b5‑1 trading plan entered into by James Edgemond on October 31, 2025, indicating the transactions were pre‑scheduled rather than timed discretionarily.

How many United Therapeutics shares does the CFO hold after these transactions?

After completing the reported exercise and sales, James Edgemond directly held 18,876 shares of United Therapeutics common stock. This figure comes from the post‑transaction ownership column associated with the final reported sale on March 26, 2026.

Were there any remaining derivative positions for the United Therapeutics CFO after this Form 4?

The filing’s derivative summary is empty, and it shows one option exercise for 10,000 shares. This indicates the reported derivative position linked to this transaction was fully exercised, with no remaining unexercised options disclosed in this specific Form 4 data.